Navigation Links
Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
Date:8/13/2013

SAN DIEGO, Aug. 13, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial results, its first as a public company.

"The second quarter was transformative for Ambit.  We successfully completed our initial public offering, which put us on solid financial footing to continue the clinical development of quizartinib, our lead drug candidate," said Michael Martino, president and Chief Executive Officer. "Our primary goal is to make this potentially important new therapy available to patients with acute myeloid leukemia (AML), who are in need of better treatment options."

Second Quarter Highlights and Recent Events

  • Raised net proceeds of approximately $83 million after completion of an initial public offering of common stock, including $25 million in a concurrent private placement with existing investors
  • Presented results from the Phase 2 ACE study of quizartinib in patients with relapsed or refractory AML at the annual meeting of the American Society of Clinical Oncology (ASCO) and at the 18th Congress of the European Hematology Association
  • Completed top line analyses from the Phase 2b clinical trial of quizartinib
  • Held a Type C meeting with the FDA in June.  FDA requested additional information and analyses be presented at end of Phase 2 (EOP2) meeting
  • Submitted four abstracts to the American Society of Hematology (ASH) for the annual meeting in December 2013
  • Quizartinib Program UpdateThe Company has completed preliminary top line analyses of the Phase 2b clinical trial of qu
    '/>"/>

    SOURCE Ambit Biosciences Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
    2. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
    3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
    4. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
    5. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
    6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
    7. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    8. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    9. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
    10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
    11. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... HARRISBURG, Pa. , Dec. 24, 2014  Commonwealth Cornerstone ... New Markets Tax Credits transaction on Tuesday to help fund ... Health Network (PHN) in Sharon . ... operating in Pennsylvania . It is the ... district, with more than 150 people on staff. ...
    (Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
    (Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
    Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
    (Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
    (Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
    (Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier ... special occasion outfits, unveils 65 new bridesmaid dresses ... discounted prices, up to 80% off. , Yunx.co.uk’s dresses ... fashionable designs, gorgeous looks and delicate craftsmanship. These new ... devoted to designing and offering high-quality women’s dresses with ...
    (Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
    (Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, ... from sex for one year will be allowed to donate blood ... reverse a 31-year ban on donations from men who have sex ... its intention to release a new draft guidance in early 2015 ... men. The FDA is changing its policy based on data ...
    Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
    ... Director of the Lucero Latino Mental Health Training Program at ... was appointed today to the Massachusetts Health Disparities Council by ... of the Health Disparities Council. , , ... to be named to the Council, which was established by ...
    ... N.J., Dec. 15 Daiichi Sankyo, Inc., announced ... hypertension disease management program developed in accordance with ... Certification from the National Committee for Quality Assurance ... health care quality. NCQA certification signifies that the ...
    ... M.D. Anderson Cancer Center To Evaluate Surgery vs. CyberKnife ... ... 15, 2008 -- CyberKnife Center of Palm Beach, http://www.cyberknifepalmbeach.com , ... landmark study comparing traditional surgery and CyberKnife® radiosurgery treatment outcomes in ...
    ... Dec. 15 "We believe that hair loss for,both men ... was to find a,non-surgical approach to help our clients that ... We selected the Revage 670(TM),because it is the only ... proved it works (supported by Harvard Medical, Northwestern,University , ...
    ... 15 DaVita Inc.,(NYSE: DVA ), today ... of,Health and Human Services, Office of Inspector General ("OIG") ... connection with the civil,investigation by the Department of Justice ... Georgia previously reported in the Company,s,Quarterly Report on 10-Q ...
    ... than during the day, study says , , MONDAY, Dec. 15 ... sick body good, new research says. , Stanford University research ... bacteria the hardest at night and the least during the ... American Society for Cell Biology annual meeting, in San Francisco. ...
    Cached Medicine News:Health News:Latino Psychologist Appointed to Mental Health Post in Commonwealth 2Health News:Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program 2Health News:Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program 3Health News:First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients 2Health News:First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients 3Health News:DaVita Inc. Announces Receipt of DOJ Subpoena in Connection with Previously Reported Investigation 2Health News:Immune System Works Better at Night 2
    The HT-PB is a implantable bipolar tined permanent pacing lead for stimulation of the ventricle....
    The Guidant Fineline leads are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
    Steroid-eluting, screw-in pacing lead...
    ... The Guidant Flextend ... transvenous pace/sense lead with ... The extendable/retractable helix design ... possibilities for permanent implantation ...
    Medicine Products: